Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
To date no specific treatment has been proven to be effective for Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-Cov-2) infection. It is possible that convalescent plasma that
contains antibodies to SARS-Cov-2 might be effective against the progression of infection.
Promising results have been shown by preliminary data from China cases. The investigators
planned to compare effectiveness of adding COVID-19 convalescent plasma to standard therapy
protocol (STP) versus adding plasma donated in pre-COVID era versus STP alone in patient with
COVID-19 within 5 days from the onset of respiratory distress. STP at enrolment is the best
evidence based therapy approved for treatment of COVID patients by regional Health system
emergency committee.
Phase:
Phase 2
Details
Lead Sponsor:
Azienda Ospedaliera Città della Salute e della Scienza di Torino